Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeuroBiogen
South Koreaneurobiogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroBiogen's lead candidate KDS2010, a reversible selective MAO-B inhibitor, has shown promising cognitive improvement in preclinical and Phase 1 studies. It is currently in Phase 2 clinical trials in obesity and Alzheimer's disease, with evidence suggesting reduction in astrocytic GABA signaling and neuroinflammation, translating to improved learning and memory in trial subjects.[2][3][6]
- Therapeutic areas
- OncologyNeurologyEndocrinologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Scilex Bio (part of Scilex Holding Company)
Beyond the preview
Go deeper on NeuroBiogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroBiogen.